Everolimus in clinical practice - Renal transplantation

Nephrology Dialysis Transplantation

Volumn 21, Issue SUPPL. 3, 2006, Pages

  Pascual, Julio ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Acute rejection; Everolimus; Mammalian target of rapamycin inhibitors; Proliferation signal inhibitors; Renal transplantation; Sirolimus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; EVEROLIMUS; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POVIDONE IODINE; PROLIFERATION SIGNAL INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFESTYLE; LUNG FIBROSIS; LYMPHOCELE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MICROCYTIC ANEMIA; NONHUMAN; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; SKIN CANCER; STEADY STATE; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT;

ACUTE DISEASE; CALCINEURIN; CELL PROLIFERATION; CLINICAL TRIALS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 33745801296     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl300     Document Type: Article

References (27)

1. Pascual J, Boletis IN, Campistol JM. Everolimus (Certicana®) in renal transplantation: A review of clinical trial data, current usage and future directions. Transplant Rev 2006; 20: 1-18
2. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T on behalf of the 156 Study Group. Everolimus and reducedexposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332-1340
3. Vítko S, Weimar W et al. Everolimus (Certicana®) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004; 78: 1532-1540
4. Lorber MI, Mulgaonkar S, Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252
5. Vítko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
6. Vítko S, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
7. Lorber MI, Ponticelli C, Whelchel J et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant 2005; 19: 145-152
8. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, O'Bannon LF, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: A clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42: 95-99
9. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1756
10. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875
11. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517-2523
12. Bellosta S, Arnaboldi L, Canavesi M et al. Everolimus affects cholesterol homeostasis in macrophages. 7th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Denver, Co, USA, April 27-29, 2006
13. Kasiske B, Cosio FG, Beto J et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4 [Suppl 7]: 13-53
14. Ferri N, Granata A, Pirola C, Pfister PJ, Dorent R, Corsini A. In vitro enhanced antiproliferative activity of everolimus by fluvastatin on arterial smooth muscle cells. International Symposium on Atherosclerosis, Rome, Italy, June 18-22, 2006
15. Keane WF. Proteinuria: Its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97-S105
16. Kahan BD for The Rapamune Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. Lancet 2000; 356: 194-202
17. Lezaic V, Djukanovic L, Pavlovic-Kentera V. Recombinant human erythropoietin treatment of anemia in renal transplant patients. Ren Fail 1995; 17: 705-714
18. Champion L, Stern M, Israel-Biet D et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Int Med 2006; 144: 505-509
19. Garrean S, Massad MG, Tshibaka M et al. Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 2005; 19: 698-703
20. Haydar AA, Denton M, West A et al. Sirolimus-induced pneumonitis: Three cases and a review of the literature. Am J Transplant 2004; 4: 137-139
21. Morelon E, Stern M, Israel-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001; 72: 787-790
22. Pham PTT, Pham PCT, Danovitch GM et al. Sirolimusassociated pulmonary toxicity. Transplantation 2004; 77: 1215-1220
23. Teruel JL, Escobar EM, Quereda C, Mayayo T, Ortuño J. A simple and safe method for management of lymphocele after renal transplantation. J Urol 1983; 130: 1058-1059
24. Kandaswamy R, Melancon JK, Dunn T et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients - an interim analysis. Am J Transplant 2005; 5: 1529-1536
25. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
26. Schena FP, Wali RK, Pascoe MD, Alberu J, del Carmen Rial M. the Sirolimus Renal Conversion Trial Study Group. A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients. Am J Transplant 2005; 5 [ [Suppl 11]: A1008
27. Campistol JM, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589